These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32795465)

  • 1. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.
    Zhu GG; Ramirez D; Chen W; Lu C; Wang L; Frosina D; Jungbluth A; Ntiamoah P; Nafa K; Boland PJ; Hameed MR
    Hum Pathol; 2020 Oct; 104():73-83. PubMed ID: 32795465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
    Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
    Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.
    Hung YP; Diaz-Perez JA; Cote GM; Wejde J; Schwab JH; Nardi V; Chebib IA; Deshpande V; Selig MK; Bredella MA; Rosenberg AE; Nielsen GP
    Am J Surg Pathol; 2020 Sep; 44(9):1213-1223. PubMed ID: 32427623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.
    van Wulfften Palthe ODR; Tromp I; Ferreira A; Fiore A; Bramer JAM; van Dijk NC; DeLaney TF; Schwab JH; Hornicek FJ
    Spine J; 2019 May; 19(5):869-879. PubMed ID: 30445184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.
    Wen X; Cimera R; Aryeequaye R; Abhinta M; Athanasian E; Healey J; Fabbri N; Boland P; Zhang Y; Hameed M
    Genes Chromosomes Cancer; 2021 Dec; 60(12):796-807. PubMed ID: 34392582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
    Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
    Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of histopathological parameters, genome-wide copy number alterations, and variants in genes involved in cell cycle regulation in chordomas of the skull base and sacrum.
    Salle H; Durand S; Durand K; Bourthoumieu S; Lemnos L; Robert S; Pollet J; Passeri T; Khalil W; Froelich S; Adle-Biassette H; Labrousse F
    J Neuropathol Exp Neurol; 2023 Mar; 82(4):312-323. PubMed ID: 36779322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of H3K27 trimethylation in a distinct group of de-differentiated chordoma of the skull base.
    Makise N; Shimoi T; Sunami K; Aoyagi Y; Kobayashi H; Tanaka S; Kawai A; Yonemori K; Ushiku T; Yoshida A
    Histopathology; 2023 Feb; 82(3):420-430. PubMed ID: 36217885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
    Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonality studies in sacral chordoma.
    Klingler L; Trammell R; Allan DG; Butler MG; Schwartz HS
    Cancer Genet Cytogenet; 2006 Nov; 171(1):68-71. PubMed ID: 17074594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
    Yang Y; Niu X; Li Y; Liu W; Xu H
    Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notochordal cell derived lesions: a 55-year casuistic analysis of 50 cases with radiologic-pathologic correlation in a tertiary referral hospital, and literature review.
    Pena-Burgos EM; Torena Lerchundi N; Fuentes-Sánchez J; Tapia-Viñe M; Fernández-Baíllo N; Pozo-Kreilinger JJ
    Eur Spine J; 2024 Sep; 33(9):3315-3323. PubMed ID: 39048841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in the operative management of dedifferentiated sacral chordomas.
    Kayani B; Sewell MD; Hanna SA; Saifuddin A; Aston W; Pollock R; Skinner J; Molloy S; Briggs TW
    Neurosurgery; 2014 Sep; 75(3):269-75; discussion 275. PubMed ID: 24867206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
    Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
    J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
    Rinner B; Froehlich EV; Buerger K; Knausz H; Lohberger B; Scheipl S; Fischer C; Leithner A; Guelly C; Trajanoski S; Szuhai K; Liegl B
    Int J Oncol; 2012 Feb; 40(2):443-51. PubMed ID: 22002331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
    Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
    Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
    Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
    Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.
    Du J; Xu L; Cui Y; Liu Z; Su Y; Li G
    J Clin Pathol; 2019 Jan; 72(1):66-74. PubMed ID: 30355586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
    Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
    J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiles and clinical presentation of chordoma.
    Koka H; Zhou W; McMaster ML; Bai J; Luo W; Klein A; Zhang T; Hua X; Li X; Wang D; Xiong Y; Jones K; Vogt A; Hicks B; Parry D; Goldstein AM; Yang XR
    Acta Neuropathol Commun; 2024 Aug; 12(1):129. PubMed ID: 39135136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.